Related Experiment Videos
Development of antiviral treatment strategies in murine models
R M Ruprecht1, J A Koch, P L Sharma
1Laboratory of Viral Pathogenesis, Dana-Farber Cancer Institute, Boston, MA.
Abstract:
Murine models with type C murine leukemia viruses have been used to develop major new prophylactic and therapeutic strategies in vaccination, drug therapy of acute virus exposure and chronic viremia, combination therapy, prevention of maternal transmission, and therapy targeted to the central nervous system. Transgenic mice expressing either the whole human immunodeficiency virus type 1 (HIV-1) provirus or subgenomic sequences allow the in vivo analysis of selected HIV-1 functions. The full replicative cycle of HIV-1 can be studied in human/mouse chimerae which were created by transplanting human hematolymphoid cells into SCID mice. The chimeric SCID mouse models have been used successfully to evaluate anti-HIV-1 drugs. The role of the various murine retrovirus systems in the development of anti-HIV-1 and anti-AIDS therapies is summarized.
Insights
Murine models, including transgenic and chimeric SCID mice, are crucial for developing new HIV-1 (human immunodeficiency virus type 1) prophylactic and therapeutic strategies. These models enable in vivo analysis and drug evaluation for combating HIV/AIDS.
Area of Science:
- Virology
- Immunology
- Animal Models
Background:
- Murine models utilizing type C murine leukemia viruses have historically advanced vaccination and drug therapy strategies.
- Human immunodeficiency virus type 1 (HIV-1) research has benefited significantly from various mouse models.
Purpose of the Study:
- To summarize the role of murine retrovirus systems in developing anti-HIV-1 and anti-AIDS therapies.
- To highlight the utility of different mouse models for studying HIV-1 infection and treatment.
Main Methods:
- Utilizing transgenic mice expressing HIV-1 provirus or subgenomic sequences for in vivo analysis.
- Employing human/mouse chimerae (SCID mice transplanted with human hematolymphoid cells) to study the full HIV-1 replicative cycle.
- Evaluating anti-HIV-1 drugs in chimeric SCID mouse models.
Main Results:
- Murine models have facilitated the development of prophylactic and therapeutic strategies for vaccination, drug therapy, combination therapy, and CNS-targeted treatment.
- Transgenic mice allow in vivo analysis of specific HIV-1 functions.
- Chimeric SCID mice successfully support the full HIV-1 replicative cycle and have been used to evaluate anti-HIV-1 drugs.
Conclusions:
- Murine retrovirus systems are indispensable tools in advancing anti-HIV-1 and anti-AIDS therapies.
- The development and application of specialized mouse models continue to be critical for HIV/AIDS research and treatment innovation.